HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (4- (4- tert- butoxycarbonylpiperazin- 1- yl)phenyl)- (2- chloro- 5- nitrophenyl)carboxamide

a scavenger receptor class B type I blocker; structure in first source

Also Known As:

R-138329

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - N-(4-(4-tert-butoxycarbonylpiperazin-1-yl)phenyl)-(2-chloro-5-nitrophenyl)carboxamide: 2

Experts

1.	Abe, Koji: 2 articles (10/2007 - 12/2006)
2.	Amemiya, Yoshiya: 2 articles (10/2007 - 12/2006)
3.	Inaba, Toshimori: 2 articles (10/2007 - 12/2006)
4.	Kitayama, Ken: 2 articles (10/2007 - 12/2006)
5.	Nishizawa, Tomohiro: 2 articles (10/2007 - 12/2006)
6.	Oda, Tomiichiro: 2 articles (10/2007 - 12/2006)
7.	Wakabayashi, Kenji: 2 articles (10/2007 - 12/2006)
8.	Ubukata, Naoko: 1 article (10/2007)
9.	Uchiyama, Minoru: 1 article (10/2007)
10.	Yamada, Makiko: 1 article (10/2007)

Related Diseases

1.	Atherosclerosis 12/01/2006 - "The results of quantitative analysis of atherosclerosis lesion areas were: control, 102691 +/-22871 microm(2) (n = 10); R-138329 0.01%, 119792+/-30842 microm(2) (n = 9); R-138329 0.03%, 141346+/-21934 microm(2) (n = 10); and R-138329 0.10% 203732+/- 36326 microm(2) (n = 10). "
2.	Hepatocellular Carcinoma (Hepatoma) 10/01/2007 - "In vitro analysis showed that R-154716, a metabolite of R-138329, dramatically inhibited the uptake of [(3)H]COE-labeled HDL in McA-RH 7777 rat hepatoma cells. "

Related Drugs and Biologics

1.	R-154716